Recent studies have highlighted the importance of CD8a+ DCs and tumor-resident CD103+ DCs in antitumor immunity due to their ability to secrete chemokines such as CXCL10, which recruit T cells to the tumor, and cytokines such as IL-12 to enhance the type I inflammatory state of infiltrating T cells (13, 14). The gene discussed is CXCL10; the disease is neoplasm.